Chemotherapy combined with anti-HER2 therapy is strongly recommended as an adjuvant therapy for elderly patients with HER2-positive breast cancer, although treatment should be individualized based on prognosis, global health status, and patient preference (SoR: 1, SoE: weak). Here, ERBB2 is linked to breast carcinoma.